Examples include analyses of histopathology slides to classify molecular subtypes of lung and colorectal cancer, evaluation of tumor microenvironments in renal cell carcinoma by quantifying immune cell infiltration, aiding in immunotherapy response predictions, detecting genetic alterations, such as EGFR and KRAS mutations in lung cancer and BRCA mutations in ovarian cancer, all of which hold significant predictive value and influence treatment decisions. This evidence concerns the gene KRAS and lung carcinoma.